Anti-Trust Approval Received for Acquisition of CLOSURE Medical Corporation by Johnson & Johnson
May 02 2005 - 7:18PM
PR Newswire (US)
Anti-Trust Approval Received for Acquisition of CLOSURE Medical
Corporation by Johnson & Johnson RALEIGH, N.C., May 2
/PRNewswire-FirstCall/ -- CLOSURE Medical Corporation (NASDAQ:CLSR)
today announced that the U.S. Federal Trade Commission had granted
early termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act with respect to the previously-announced
acquisition of CLOSURE Medical Corporation by Johnson &
Johnson. The proposed transaction is expected to close as promptly
as possible after CLOSURE Medical's special meeting of
stockholders, which is scheduled to be held on June 2, 2005,
subject to the remaining closing conditions. About CLOSURE Medical
Corporation CLOSURE Medical Corporation is a global leader in the
development and manufacture of innovative biomaterial-based medical
devices that fulfill the needs of healthcare practitioners,
patients and consumers. For additional information on CLOSURE
Medical visit its website at http://www.closuremed.com/. This
release includes forward-looking statements that are based on
assumptions about many important factors, including the approval by
CLOSURE stockholders of the acquisition; general industry and
market conditions; general domestic and international economic
conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals and the factors listed in
CLOSURE's most recent 10-K. As such, they involve risks that could
cause actual results to differ materially. The Company does not
undertake to update its forward-looking statements. This material
is not a substitute for the proxy statement CLOSURE Medical has
filed with the Securities and Exchange Commission and is currently
mailing to stockholders. Investors are urged to read the proxy
statement, including detailed risk factors, because it contains
important information. The proxy statement and other documents
filed by CLOSURE Medical with the Securities and Exchange
Commission are available free of charge at the SEC's website,
http://www.sec.gov/, or by visiting CLOSURE Medical's website at
http://www.closuremed.com/. CLOSURE Medical and certain of its
directors, executive officers and certain other members of its
management may be deemed to be soliciting proxies from CLOSURE
Medical's shareholders in connection with the proposed transaction.
Investors may obtain a detailed list of names, affiliations and
interests of CLOSURE Medical participants in the solicitation of
proxies of CLOSURE Medical's shareholders by reading the proxy
statement. DATASOURCE: CLOSURE Medical Corporation CONTACT:
investors, Joe Allen, +1-212-691-8087, , or media, Len Hall,
+1-949-474-4300, , both of Allen & Caron Inc, for CLOSURE
Medical Corporation; or Benny Ward, CFO of CLOSURE Medical
Corporation, +1-919-876-7800 Web site: http://www.closuremed.com/
Copyright
Closure Medical (NASDAQ:CLSR)
Historical Stock Chart
From Apr 2024 to May 2024
Closure Medical (NASDAQ:CLSR)
Historical Stock Chart
From May 2023 to May 2024